Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

BACKGROUND: This study aimed to reveal the prevalence of sodium-glucose co-transporter 2 (SGLT2) inhibitor treatment and its association with restenosis risk in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease. METHODS: We used the database of...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahara, Mitsuyoshi, Soga, Yoshimitsu, Fujihara, Masahiko, Iida, Osamu, Kawasaki, Daizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557214/
https://www.ncbi.nlm.nih.gov/pubmed/37798619
http://dx.doi.org/10.1186/s12933-023-01992-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557214/
https://www.ncbi.nlm.nih.gov/pubmed/37798619
http://dx.doi.org/10.1186/s12933-023-01992-4

Ejemplares similares